SCHEMBL2878558

SCHEMBL2878558

C=CCC(O)C(=O)OCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
NPSR1 Q6W5P4 2/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TSHR P16473 2/20 0.36
ALOX15 P16050 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
SOAT1 P35610 1/20 0.36
HCAR2 Q8TDS4 1/20 0.34
CYP2C9 P11712 2/20 0.34
CYP1A2 P05177 1/20 0.34
HIF1A Q16665 1/20 0.34
TRPA1 O75762 1/20 0.33
GLO1 Q04760 1/20 0.33
CPA1 P15085 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29105547 0.81 HCAR2 (0.38) ALDH1A1LMNAHCAR2
SCHEMBL18239536 0.80 TSHR (0.53) ALDH1A1NPSR1TSHRHCAR2L3MBTL1
SCHEMBL8469191 0.80 TSHR (0.53) ALDH1A1NPSR1TSHRHCAR2L3MBTL1
SCHEMBL8469724 0.80
SCHEMBL793641 0.80 ALDH1A1 (0.40) ALDH1A1NPSR1LMNAHSD17B10TSHR
SCHEMBL770455 0.80 TSHR (0.41) ALDH1A1NPSR1HSD17B10TSHRCPA1
SCHEMBL3068583 0.80
SCHEMBL891773 0.80 CPA1 (0.42) ALDH1A1NPSR1LMNAHSD17B10TSHR
SCHEMBL29059967 0.79 ALDH1A1 (0.38) ALDH1A1NPSR1LMNAHSD17B10TSHR
SCHEMBL21463245 0.79 TSHR (0.53) ALDH1A1LMNAHSD17B10TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 US disclosed
US-20250243427-A1 PRECURSORS OF PHENOLIC FRAGRANT COMPOUNDS GIVAUDAN SA (CH) 2025-07-31 US disclosed
US-20250186408-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-06-12 US disclosed
WO-2025104443-A1 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-05-22 WO disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 EP disclosed
EP-4419497-A1 PRECURSORS OF PHENOLIC FRAGRANT COMPOUNDS Givaudan SA (CH) 2024-08-28 EP disclosed
CN-118119588-A Precursors for phenolic aromatic compounds 奇华顿股份有限公司 2024-05-31 CN disclosed
EP-4333819-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY Katholieke Universiteit Leuven (BE) 2024-03-13 EP disclosed
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 WO disclosed
CN-116813823-A Supported catalyst, preparation method thereof and application thereof in photocatalytic polymerization 北京服装学院 2023-09-29 CN disclosed
US-7402608-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2008-07-22 US disclosed
US-7314943-B2 Pyran derivatives containing an exocyclic double bond MERCK PATENT GMBH (DE) 2008-01-01 US disclosed
US-7314943-B2 Pyran derivatives containing an exocyclic double bond MERCK PATENT GMBH (DE) 2008-01-01 US disclosed
US-7314943-B2 Pyran derivatives containing an exocyclic double bond MERCK PATENT GMBH (DE) 2008-01-01 US disclosed
EP-1482020-B1 Pyran derivatives with an exocyclic double bond MERCK PATENT GMBH (DE) 2006-09-06 EP disclosed
EP-1569929-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS Virochem Pharma Inc. (CA) 2005-09-07 EP disclosed
US-20050038267-A1 Pyran derivatives containing an exocyclic double bond MERCK PATENT GMBH (DE) 2005-02-17 US disclosed
US-20050009804-A1 Compounds and methods for the treatment or prevention of Flavivirus infections VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) 2005-01-13 US disclosed
EP-1482020-A1 Pyran derivatives with an exocyclic double bond MERCK PATENT GmbH (DE) 2004-12-01 EP disclosed
WO-2004052885-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VIROCHEM PHARMA INC. (CA) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009804-A1 Compounds and methods for the treatment or prevention of Flavivirus infections ZC3HAV1, ZYX, ZFX ALDH1A1 1591/4885NPSR1 3295/4885LMNA 1242/4885
US-20050038267-A1 Pyran derivatives containing an exocyclic double bond EXOC1, EDF1, EIF4A1 ALDH1A1 1096/4885NPSR1 2586/4885LMNA 618/4885
US-20250186408-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY CNR1, CNR2, CYP2J2 ALDH1A1 1412/4885NPSR1 233/4885LMNA 2454/4885
US-20250243427-A1 PRECURSORS OF PHENOLIC FRAGRANT COMPOUNDS FOS, HAAO, HPD ALDH1A1 843/4885NPSR1 1231/4885LMNA 1960/4885
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 ALDH1A1 474/4885NPSR1 508/4885LMNA 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.